Skip to main content
    A

    Actinium Pharmaceuticals Inc (ATNM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $1.49
    -0.15 (-9.45%)

    Market Cap: $51.56M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Actinium Pharmaceuticals Inc (ATNM) P/E Ratio & Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Actinium Pharmaceuticals (ATNM) trades at 4.1x trailing earnings and 1.3x sales. Its P/B of 1.5x is below its 5-year median of 2.9x. Its forward P/E is 8.5x.

    Current Multiples

    Its forward P/E is above its trailing P/E, which implies earnings per share about 51.8% lower over the next year.

    MultipleValue
    P/E (trailing)4.1x
    Forward P/E8.5x
    Price to sales1.3x
    Price to book1.5x
    EV/EBITDA1.0x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/B is 55.9% below 3.4x.

    MultipleCurrent5-year median10-year median
    P/B1.5x2.9x3.4x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 4 of the 10 year ends shown that have a P/S, its P/S ranged from 48.5x in 2024 to 471.4x in 2025. 2025 was the highest of those years.

    Year endPriceP/SP/B
    2025$1.36471.4x5.4x
    2024$1.2648.5x1.2x
    2023$5.08N/A3.9x
    2022$10.65204.4x4.1x
    2021$6.0153.7x1.8x
    2020$7.80N/A2.3x
    2019$6.55N/A6.7x
    2018$11.62N/A5.2x
    2017$19.94N/A4.3x
    2016$26.28N/A2.7x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ATNM

    What is ATNM's forward P/E ratio?

    Actinium Pharmaceuticals has a forward P/E ratio of 8.5x.

    Is ATNM stock overvalued?

    GNG's valuation label for ATNM is Undervalued.

    What is ATNM's price to sales ratio?

    Actinium Pharmaceuticals has a price to sales ratio of 1.3x.